Paramedic Drugs

Card Set Information

Author:
emtnm
ID:
38270
Filename:
Paramedic Drugs
Updated:
2010-10-01 00:00:43
Tags:
Paramedic Drugs
Folders:

Description:
NM Scope of Practice Paramedic Drugs
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user emtnm on FreezingBlue Flashcards. What would you like to do?


  1. ACETYLCYSTEINE
  2. ACETYLCYSTEINE
    CLASS OF DRUG: Mucolytic

    • INDICATIONS – Authorized for Paramedic monitoring during inter-facility transport
    • 1. Antidote to acetaminophen overdose

    • CONTRAINDICATIONS
    • 1. Hypersensitivity

    DRUG INTERACTION: None

    ADMINISTRATION: Follow dosing ordered by sending physician

    SPECIAL NOTES: Activated charcoal absorbs acetylcysteine if given PO for acetaminophen ingestion.
  3. ADENOSINE (ADENOCARD®)
    CLASS OF DRUG
    Endogenous nucleoside; antidysrhythmic
  4. ADENOSINE
    INDICATIONS
    1. Paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White syndrome.
  5. ADENOSINE
    CONTRAINDICATIONS
    1. Hypersensitivity

    2. High degree A-V block and sick sinus syndrome, unless a pacemaker is in place
  6. ADENOSINE
    ADMINISTRATION
    Adult: [6 mg] rapid IVP (1-2 seconds) followed with a 30 cc flush. May be repeated in 1-2minutes, a second dose of [12 mg] rapid IVP followed by a 30 cc flush. Single doses ofgreater than 12 mg should not be given. May be given up to three times and alwaysfollow each bolus with a 30 cc flush.

    Pediatric: Initial: [0.1 mg/kg] rapid IVP. Repeat in 2-3 minutes if no change.Second and third dose at [0.2 mg/kg] rapid IVP.
  7. ADENOSINE
    SPECIAL NOTES
    1. Use on patients with asthma, may induce bronchospasms.

    2. Safety in pregnancy is unknown.

    3. Transient dysrhythmias, such as periods of asystole, are common and self-limiting, requiring notreatment unless they persist.

    4. Side effects may include: facial flushing, headache, chest pain, dyspnea, lightheadedness, andnausea.

    5. Must be given in the IV port most proximal to the patient
  8. AMINOPHYLLINE
    CLASS OF DRUG
    Xanthine bronchodilator
  9. AMINOPHYLLINE
    INDICATIONS (Authorized for monitoring during inter-facility transport)
    1. Acute bronchospasm due to asthma

    2. Anaphylaxis with bronchospasm

    3. Wheezing in older persons, when pulmonary edema is a serious consideration

    4. COPD with exacerbation
  10. AMINOPHYLLINE
    CONTRAINDICATIONS
    1. None, when indicated.
  11. AMINOPHYLLINE
    ADMINISTRATION
    Adult: [5-7 mg/kg] IV infusion in 50 ml D5W over 20 minutes[0.5 to 0.9 mg/kg per hour] maintenance dosea. The lower dose is used for older patients, patients with liver disease, congestive heartfailure, hypovolemia, and non-smokers.b. The higher ranges are used for children and smokers.

    Pediatric: [5-6 mg/kg] IV infusion in 50 ml D5W over 20 minutes not to exceed 12 mg/kg in a 24hour period
  12. AMINOPHYLLINE
    SPECIAL NOTES
    1. Aminophylline monitoring is used only during inter-facility transports.

    2. If infused too rapidly, may cause nausea, vomiting, seizures, ventricular fibrillation, andcirculatory collapse. Monitor constantly. Do not exceed 25 mg/min.

    3. Aminophylline may cause an initial drop in arterial oxygen concentration. Always have patienton oxygen before administration.

    4. Nausea is an early sign of toxicity. Seizures are a late sign of toxicity.
  13. AMIODARONE (CORDARONE®)
    CLASS OF DRUG
    Antiarrhythmic
  14. AMIODARONE (CORDARONE®)
    INDICATIONS1. Pulseless VF/VT refractory to initial electrical therapy2. Unstable VT refractory to lidocaine and/or electrical therapy
    1. Pulseless VF/VT refractory to initial electrical therapy

    2. Unstable VT refractory to lidocaine and/or electrical therapy
  15. AMIODARONE (CORDARONE®)
    CONTRAINDICATIONS
    1. None, if the patient is in cardiac arrest with VF or VT.

    2. High degree AV blocks or sinus node dysfunction with marked bradycardia unless a functionalpacemaker is in place.

    3. Congestive heart failure
  16. AMIODARONE (CORDARONE®)
    ADMINISTRATION
    Adult:Pulseless VT/VF [300 mg] initial bolus IVP or IO after epinephrine. May re-bolus with[150mg] once.Sustained VT [150 mg] over 10 minutes. May re-bolus every 10 minutes as needed upto a maximum dose of 15 mg/kg/day.Maintenance infusion: [0.5 mg/kg], 540 mg IV over 18 hours

    Pediatric:Pulseless VT/VF [5mg/kg] IVP or IO. May re-bolus every 3-5 minutes to a maximum of20 mg/kg/24 hoursSustained VT [5 mg/kg] IVP or IO over 20-60 minutes. May repeat as needed to amaximum dose of 20 mg/kg /24 hours.
  17. AMIODARONE (CORDARONE®)
    SPECIAL NOTES
    1. Must be drawn up slowly to avoid 'bubbles" do not shake the ampule for the same reason.

    2. Must be given concurrently with epinephrine in the pulseless patient.

    3. Can not be administered via ET tube.

    4. Hypotension and bradycardia can occur on patients with a pulse.
  18. ATROPINE SULFATE
    CLASS OF DRUG
    Anticholinergic (parasympatholytic)
  19. ATROPINE SULFATE
    INDICATIONS
    1. Symptomatic sinus bradycardia or A-V Blocks

    2. Bradycardia associated with PEA

    3. Asystole

    4. Anticholinesterase poisonings - organophosphate, mushrooms (certain types), and nerve gases

    5. Adjunct in the treatment of bronchial asthma
  20. ATROPINE SULFATE
    CONTRAINDICATIONS
    1. None, when indicated.
  21. ATROPINE SULFATE
    ADMINISTRATION
    1. Cardiac Indications:Adult: [0.5 mg] IV, every 3-5 minutes: max 3.0 mg (0.04 mg/kg) for bradycardia.[1.0 mg] rapid IVP or IO, [2 to 3 mg diluted in 10ml NS] ET, every 3-5 minutes for(asystole, PEA < 60 bpm)Pediatric: [0.02 mg/kg] IVP or IO for 2 dosages. Minimum of 0.1 mg and maximum of 0.5 mg

    2. Anticholinesterase poisoning:Adult: [2.0 mg] IVP repeated until symptoms abatePediatric: [0.05 mg/kg] IV, ET, or IO, repeated until symptoms abate

    3. Mushroom Poisoning:Adult: [2 mg] IVP, repeated to doses sufficient enough to control parasympathomimeticsigns
  22. ATROPINE SULFATE
    SPECIAL NOTES
    1. May be not be effective with high degree A-V block (2nd degree type II, 3rd degree) - do notdelay pacing.

    2. Bradycardia in the setting of an acute MI is common and probably beneficial. Don't treat the rateunless there are signs of poor perfusion (i.e. low blood pressure, mental confusion). Chest paincould be due to an AMI or to poor perfusion caused by the bradycardia itself.

    • 3. Atropine increases the workload and myocardial 02 consumption of heart. Beware of patientswho have an
    • ischemic myocardium. Administer supplemental oxygen.
  23. BETA BLOCKING AGENTS
    CLASS OF DRUG
    Beta-adrenergic blocker
  24. BETA BLOCKING AGENTS
    INDICATIONS (Intra-facility Transport Drug)
    1. Used alone or in combination with other agents in the management of hypertension.

    2. Management of angina pectoris.

    3. Prevention of myocardial infarction.
  25. BETA BLOCKING AGENTS
    CONTRAINDICATIONS
    1. Uncompensated congestive heart failure.

    2. Pulmonary edema

    3. Cardiogenic shock

    4. Bradycardia or heart block
  26. BETA BLOCKING AGENTS
    ADMINISTRATION
    1. Selected drug, administration, and drug dosage must be determined by Medical Direction prior totransport.
  27. BETA BLOCKING AGENTS
    SPECIAL NOTES
    1. Use cautiously within 14 days of MAO inhibitor therapy
  28. BENZODIAZEPINES
  29. BENZODIAZEPINES
  30. BENZODIAZEPINES
  31. BENZODIAZEPINES
  32. BENZODIAZEPINES
    CLASS OF DRUG
    Anticonvulsant, anti-anxiety, sedative, muscle relaxant
  33. BENZODIAZEPINES
    INDICATIONS
    1. Control of seizures2. Sedation for cardioversion3. To facilitate intubation or in conjunction with paralytics for rapid sequence intubation. (withspecial skills approval only)4. Reduction of anxiety5. Skeletal muscle relaxant
  34. BENZODIAZEPINES
    CONTRAINDICATIONS
    1. Hypersensitivity

    2. CNS depression
  35. BENZODIAZEPINES
    ADMINISTRATION
    • AdultsDiazepam (Valium®): [2-10 mg] IVP, slow with IV running open
    • Lorazepam (Ativan®): [2 - 4 mg] (0.05 mg/kg) IVP, slow with IV running open
    • Midazolam (Versed®): [1-5 mg] IVP, slow (over 2 minutes) with IV running open
    • Note: HIGHER DOSES MAY BE REQUIRED

    • Pediatric:Diazepam: > 5 yrs. of age, [1 mg]every 2-5 minutes to a max. of 10 mg. Repeat every 2-4 hrs.
    • Diazepam: < 5 yrs. of age, [0.2 mg] every 2-5 minutes to a maximum of 5 mg.
    • a. Rectal dosage [0.5 mg/kg] may be warranted in seizure patients if no venous access isavailable. Onset of action by this route may be delayed.
    • b. Apnea in children after diazepam administration may occur
    • Lorazepam: 0.05-0.1 mg/kg IV to a maximum 4 mg. Onset 2-3 minutes. Duration 12-24 hours.
  36. BENZODIAZEPINES
    SPECIAL NOTES
    1. Should not be mixed with other agents, or diluted with intravenous solutions. Give through theproximal end of IV tubing, then flush well.

    2. Most likely to produce respiratory depression on patients who have taken other depressant drugs,especially alcohol and barbiturates.

    3. It can cause local venous irritation. Use relatively large veins.

    4. Has short half- life. Additional doses may be necessary.

    5. Utilization of pharmacological agents for the primary purpose of sedation, induction, ormuscle relaxation to facilitate placement of an advanced airway requires Medical DirectionCommittee Special Skills approval.
  37. CALCIUM PREPARATIONS
    CLASS OF DRUG
    Electrolyte
  38. CALCIUM PREPARATIONS
    INDICATIONS
    1. Used as antidote for calcium channel blocker overdoses

    2. Magnesium sulfate overdoses

    3. Black Widow spider bite
  39. CALCIUM PREPARATIONS
    1. Hypercalcemia

    2. Absence of indications
  40. CALCIUM PREPARATIONS
    ADMINISTRATION
    • Calcium GluconateAdult: [5 - 10 ml] SLOW IVP (Do Not Exceed 2 ml/minute) repeat if necessary after5 - 10 min.Pediatric: [0.6 ml/kg] SLOW IVP of 10% solution
    • Calcium Chloride:Adult: [5-10ml] by SLOW IVP. Repeat every 10 minutes as needed (1 ml of 10% =100 mg of calcium chloride).
    • Pediatric: [0.2 ml/kg] (10% solution) by SLOW IVP. Repeat once in 10 minutes ifneeded.
    • NOTE: RAPID INJECTION CAN CAUSE HYPOTENSION, BRADYCARDIA ANDDEATH.
  41. CALCIUM PREPARATION
    SPECIAL NOTES
    1. It is best to warm the drug to body temperature prior to administration.

    2. If heart is beating, rapid administration of calcium salts can produce bradycardia and/or arrest.

    3. May increase cardiac irritability, i.e., PVC's, particularly in the presence of digitalis.

    4. Local infiltration will cause tissue necrosis.
  42. DILTIAZEM HCL (CARDIZEM®)
    CLASS OF DRUG
    Calcium Channel Blocker; Coronary Vasodilator, Antidysrhythmic
  43. DILTIAZEM HCL (CARDIZEM®)
    INDICATIONS (Authorized for monitoring during inter-facility transport)
    1. Atrial Fibrillation or Atrial Flutter

    2. Paroxysmal Supraventricular Tachycardia

    3. Angina due to coronary artery spasm
  44. DILTIAZEM HCL (CARDIZEM®)
    CONTRAINDICATIONS
    1. Sick sinus syndrome except in the presence of a functioning ventricular pacemaker.

    2. Patients with second- or third degree AV block except in the presence of a functioningventricular pacemaker.

    3. Patients with severe hypotension or cardiogenic shock

    4. Patients who have demonstrated hypersensitivity to the drug

    5. Intravenous diltiazem and intravenous beta-blockers should not be administered together or inclose proximity (within a few hours).

    6. Patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as inWPW syndrome or short PR syndrome

    7. Patients with ventricular tachycardia
  45. DILTIAZEM HCL (CARDIZEM®)
    ADMINISTRATION
    Adult: [0.25 mg/kg] as a bolus administered over 2 minutes (20 mg is a reasonable dose for theaverage patient). If response is inadequate, a second dose may be administered after 15minutes. The second bolus dose of diltiazem HCl injectable should be [0.35 mg/kg]actual body weight administered over 2 minutes (25 mg is a reasonable dose for theaverage patient).For continued reduction of the heart rate (up to 24 hours) in patients withatrial fibrillation or atrial flutter, an intravenous infusion of diltiazem HCl injectable maybe administered. Immediately following bolus administration of [20 mg] (0.25 mg/kg) or[25 mg] (0.35 mg/kg) diltiazem HCl injectable and reduction of heart rate, begin anintravenous infusion of diltiazem HCl injectable. The recommended initial infusion rateof diltiazem HCl injectable is [10 mg/h]. Some patients may maintain response to aninitial rate of 5 mg/h. The infusion rate may be increased in 5 mg/h increments up to 15mg/h as needed, if further reduction in heart rate is required. The infusion may bemaintained for up to 24 hours.

    Pediatric: Not usually used.
  46. DILTIAZEM HCL (CARDIZEM®)
    SPECIAL NOTES
    1. When given to a conscious patient, they will almost always produce nausea, vomiting andhypotension.
  47. DOBUTAMINE (DOBUTREX®)
    CLASS OF DRUG
    Sympathomimetic, beta agonist
  48. DOBUTAMINE (DOBUTREX®)
    INDICATIONS (Authorized for monitoring during inter-facility transport)
    1. Primary indication is cardiogenic shock, with pulmonary edema.
  49. DOBUTAMINE (DOBUTREX®)
    CONTRAINDICATIONS
    1. None when indicated. Use cautiously in AMI and atrial fibrillation.
  50. DOBUTAMINE (DOBUTREX®)
    ADMINISTRATION (An infusion pump must be used)
    .Adult: [2 - 20 mcg/kg/min] (mix 1 ampule (250 mg) in 250 ml of D5W - resulting in aconcentration of 1mg/ml = 1000 mcg/ml)

    Pediatric: [1.0 mcg/kg per minute] (6 x body weight (kg) equals milligrams to add to D5W tocreate a total volume of 100ml). Infuse at 1mL/h.
  51. DOBUTAMINE (DOBUTREX®)
    SPECIAL NOTES
    1. Dobutamine should be titrated to effect.
  52. DOPAMINE HYDROCHLORIDE (DOPASTAT®, INTROPIN®)
    CLASS OF DRUG
    Potent sympathomimetic, dopaminergic
  53. DOPAMINE HYDROCHLORIDE (DOPASTAT®, INTROPIN®)
    INDICATIONS
    1. Primary indication is cardiogenic shock.

    2. May be useful for other forms of shock

    3. May be useful, at low doses, in renal failure

    4. Used for refractory bradycardia unresponsive to atropine, and when pacing is unavailable.
  54. DOPAMINE HYDROCHLORIDE (DOPASTAT®, INTROPIN®)
    CONTRAINDICATIONS
    1. Tachydysrhythmias

    2. Pheochromocytoma
  55. DOPAMINE HYDROCHLORIDE (DOPASTAT®, INTROPIN®)
    ADMINISTRATION
    Adult: IV infusion ONLY - Mix 400 mg in 250 ml D5W or NS to produce a concentration of1600 mcg/ml. Infusion rates [2.0-20.0 mcg/kg/min] titrated to desired effect. (Otherconcentrations are used, so know what you are using). Use microdrip chamber or aninfusion pump.

    Pediatric: [1.0 mcg/kg per minute] (6 x body weight (kg) equals milligrams to add to D5W tocreate a total volume of 100ml). Infuse at 1mL/h.
  56. DOPAMINE HYDROCHLORIDE (DOPASTAT®, INTROPIN®)
    SPECIAL NOTES
    1. Higher doses can cause central vasoconstriction limiting renal blood flow.
  57. EPINEPHRINE (ADRENALINE®)
    CLASS OF DRUG
    Sympathomimetic
  58. EPINEPHRINE (ADRENALINE®)
    INDICATIONS
    • 1. Severe Bronchospasm
    • 2. Bronchospasms unresponsive to albuterol
    • 3. Anaphylaxis
    • 4. Cardiac Arrest
    • 5. Symptomatic bradycardia
  59. EPINEPHRINE (ADRENALINE®)
    CONTRAINDICATIONS
    1. None when indicated.
  60. EPINEPHRINE (ADRENALINE®)
    ADMINISTRATION
    Cardiac Arrest
    Adult: [1 mg](1:10,000) every 3 - 5 minutesIV or IO preferred, may be given ET (2 - 2 1/2 times IV dose)

    Pediatric: Initial: IV/IO 0.01 mg/kg (1:10,000) every 3-5 minutesET 0.1 mg/kg (1:1000)
  61. EPINEPHRINE (ADRENALINE®)
    ADMINISTRATION
    Bradycardia
    Adult: [1 mg/ 1:1,000] in 250 cc NS or D5W administered at 2 - 10 mcg/min

    Pediatric: [0.1-0.2 mcg/kg/minute] (0.6 x body weight (kg) equals milligrams to addto D5W to create a total volume of 100 m). Infuse at 1mL/h
  62. EPINEPHRINE (ADRENALINE®)
    ADMINISTRATION
    Bronchospasm/Anaphylaxis
    Adult: [0.3 mg] (1:1,000) SQ or IM using a pre-filled device.[0.3 mg] (1:10,000) IV or 1 mg ET (IF SEVERE OR NORESPONSE TO SQ/IM) Repeat PRN (Paramedic Only)

    Pediatric: [0.01 mg/kg (1:1000)], SQ To a maximum dose of 0.3 mg/dose
  63. EPINEPHRINE (ADRENALINE®)
    SPECIAL NOTES
    • 1. When used for allergic reactions, increased cardiac workload can precipitate angina and/or AMIin susceptible individuals.
    • 2. Due to peripheral vasoconstriction, it should be used with caution on patients with peripheralvascular insufficiency.
    • 3. Wheezing in an elderly person is pulmonary edema or pulmonary embolus until provenotherwise.
  64. EPOPROSTENOL SODUIM (FLOLAN®)
    CLASS OF DRUG
    Prostaglandin (vasodilator)
  65. EPOPROSTENOL SODUIM (FLOLAN®)
    INDICATIONS (Administration of patient’s own medication only)
    1. Management of primary pulmonary hypertension in patients currently being treated withcontinuous Flolan® infusion.
  66. EPOPROSTENOL SODUIM (FLOLAN®)
    CONTRAINDICATIONS
    • 1. Patients with a known hypersensitivity.
    • 2. Patients with CHF secondary to left ventricular systolic dysfunction.
    • 3. Patients who develop pulmonary edema secondary to Flolan® use.
  67. EPOPROSTENOL SODUIM (FLOLAN®)
    ADMINISTRATION
    • 1. Flolan® must be reconstituted from powder form with a specific diluents.
    • 2. Specific dosing must be obtained from the patient.
  68. EPOPROSTENOL SODUIM (FLOLAN®)
    SPECIAL NOTES
    • 1. Most patients treated with Flolan® utilize an ambulatory infusion pump.
    • 2. In the event the patient is found unconscious the patient should be assessed for continuousinfusion through a central line. If not, a designated peripheral line should be initiated andinfusion continued.
    • 3. Flolan® is incompatible with all other medications and must be administered through adesignated IV line.
    • 4. Added hypotension may occur with antihypertensive, diuretics or other vasodilators.
  69. FUROSEMIDE (LASIX®)
    CLASS OF DRUG
    Potent loop diuretic
  70. FUROSEMIDE (LASIX®)
    INDICATIONS
    • 1. Pulmonary edema
    • 2. Hypertensive emergencies (AMI, APE, or encephalopathy)
  71. FUROSEMIDE (LASIX®)
    CONTRAINDICATIONS
    • 1. Hypovolemia
    • 2. Hypokalemia
    • 3. Hypotension
  72. FUROSEMIDE (LASIX®)
    ADMINISTRATION
    Adult: For patients not currently taking furosemide, [20 - 40 mg] slow IVP or [0.5 - 1.0 mg/kg]slow IVP. Use lower dose if no previous exposure to the drug. If the patient is currentlytaking furosemide, double the PO dose. Patients already on oral diuretics may requirehigher doses. You may repeat one dose PRN.

    Pediatric: [1.0 mg/kg] slow IVPIt may be repeated in 6 - 8 hours.
  73. FUROSEMIDE (LASIX®)
    SPECIAL NOTES
    • 1. It can lead to profound diuresis with resultant shock and electrolyte depletion (particularly K+).Therefore, do not use in hypovolemic states and monitor closely, particularly after IVadministration.
    • 2. It should be used in children or pregnant women cautiously.
    • 3. If patient unconscious, must have Foley catheter in place and unobstructed urine outflow. Advisethe physician if urine is bloody. Trauma to kidneys and urinary system makes the use of furosemide more hazardous.
  74. GLUCAGON
    CLASS OF DRUG
    Hormone- hyperglycemic agent
  75. GLUCAGON
    INDICATIONS
    • 1. Documented symptomatic hypoglycemia (BGL less than 60 mg/dl) when an IV cannot be started.
    • 2. Beta blocker overdose with serious signs and symptoms
    • 3. Anaphylaxis refractory to epinephrine, or on patients who have history of serious coronaryarterial disease
  76. GLUCAGON
    CONTRAINDICATIONS
    • 1. Patients who will be unable to receive supplemental glucose, orally, IV or rectally afteradministration of glucagon.
    • 2. Hypersensitivity to pork and/or beef3. Use with caution on patients with pheochromocytoma.
  77. GLUCAGON
    Note: 1 mg = 1 unit
    Hypoglycemia
    Adult: [0.5 - 1 mg] IM, SQ, IVP, may repeat in 10 - 20 minutes if no response.

    Pediatric: [0.1 mg/kg] IM, SQ, IVP, may repeat in 10 - 20 minutes if no response.

    THE PATIENT MUST BE GIVEN SUPPLEMENTAL GLUCOSE ASAP;PO, IV, OR RECTAL.
  78. GLUCAGON
    Note: 1 mg = 1 unit
    Beta Blocker Overdose
    • Adult: [3 to 10 mg] IVP over 1 minute. It. may be followed by an infusion of 2 - 5mg/hr.
    • Pediatric: [0.1 mg/kg] IVP over 1 minute, repeat in 5 minutes, if needed.
  79. GLUCAGON
    Note: 1 mg = 1 unit
    Anaphylaxis
    • Adult: [1 to 2 mg] slow IVP, may be repeated every 5 to 10 minutes.
    • Pediatric: [0.1 mg/kg up to 1 mg]. Rarely indicated
  80. GLUCAGON
    SPECIAL NOTES
    • 1. The patient must be given supplemental glucose ASAP; PO, IV, or Rectal. If this is not possible,the patient may be better off without glucagon. Glucagon will release all of the patient'savailable glycogen. If the patient is not provided with glucose, the subsequent hypoglycemia willbe greater than before glucagon.
    • 2. Glucagon is supplied in a powder and must be reconstituted by sterile water or saline, 1 ml ofnormal saline for each 1 mg of powder and shaken well.
  81. GLYCOPROTEIN INHIBITORS
    AGGRASTAT -TIROFIBAN®, INTEGRILIN - EPIFIBATIDE®
    CLASS OF DRUG
    Glycoprotein (GP) IIb/IIIa Inhibitor
  82. GLYCOPROTEIN INHIBITORS
    INDICATIONS (Authorized for monitoring during inter-facility transport)
    1. In combination with heparin, it is indicated for the treatment of acute coronary syndrome,including patients who are to be managed medically and in patients that are undergoing PTCA oratherectomy.
  83. GLYCOPROTEIN INHIBITORS
    CONTRAINDICATIONS
    • 1. Known hypersensitivity to any component of the product
    • 2. Active internal bleeding or a history of bleeding diathesis within the previous 30 days
    • 3. A history of intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, oraneurysm
    • 4. A history of thrombocytopenia following prior exposure to a Glycoprotein(GP) IIb/IIIa Inhibitor
    • 5. A history of stroke within 30 days or any history of hemorrhagic stroke
    • 6. Major surgical procedure or severe physical trauma within the previous month
    • 7. History, symptoms, or findings suggestive of aortic dissection
    • 8. Severe hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >110mmHg)
    • 9. Concomitant use of another parenteral GP IIb IIIa inhibitor
    • 10. Acute pericarditis
  84. GLYCOPROTEIN INHIBITORS
    ADMINISTRATION
    • 1. Requires an infusion pump
    • 2. AGGRASTAT should be administered intravenously, at an initial rate of [0.4 mg/kg/min] for 30minutes and then continued at [0.1 mg/kg/min]. For patients with severe renal insufficiency(creatinine clearance <30 ml/min), they should receive half the usual rate of infusion.
  85. GLYCOPROTEIN INHIBITORS
    SPECIAL NOTES
    • 1. Percutaneous (coronary intervention care of the femoral artery access site) therapy withGlycoprotein (GP) IIb/IIIa Inhibitors is associated with an increase in bleeding rates, particularlyat the site of arterial access for femoral sheath placements.
    • 2. Minimize vascular and other trauma. Other arterial and venous punctures, intramuscularinjections, and the use of urinary catheters, nasotracheal intubation and nasogastric tubes shouldbe minimized. When obtaining intravenous access, non-compressible sites (e.g., subclavian orjugular veins) should be avoided.

What would you like to do?

Home > Flashcards > Print Preview